Xiamen Kingdomway Group Co

The company is publicly traded on the Shenzhen Stock Exchange (ticker 002626) and chaired by founder Jiang Bin. The Jiang family holds a controlling stake through direct and affiliated shareholdings, though the precise ownership percentage fluctuates with market transactions (per public filings, 2024).

Kingdomway primarily grows through internal R&D and acquisitions of supplement brands. It has acquired Doctor's Best, Labrada, and ProSupps, and holds minority stakes in iHerb and other health players. Deal flow comes from industry relationships and strategic fit within its vertical manufacturing and distribution chain.

It is a publicly listed corporation, not a family office. The founding Jiang family directs strategy from the chairman seat, but the entity reports quarterly earnings and is subject to Chinese securities law. This gives it a governance hybrid — public accountability with family-led control.

Kingdomway targets mature supplement brands and minority stakes in e-commerce distribution platforms (e.g., iHerb). It does not operate as a venture investor; its acquisitions are typically established consumer-health brands with existing revenue and distribution.

Kingdomway focuses exclusively on health supplements and bio-synthesis — it avoids pharmaceuticals, medical devices, or financial services. Its product portfolio centers on nutraceuticals such as coenzyme Q10, NMN, astaxanthin, and ergothioneine.

These are wholly owned subsidiary brands under Kingdomway Group; each is a separate operating company with its own management, but all are consolidated into Kingdomway's financial reports. Doctor's Best is the largest brand by revenue, particularly strong in the US via Amazon and retail channels.

The company's website lists corporate social responsibility initiatives, but it does not disclose a separate foundation or charitable trust. Philanthropic activities appear integrated into the corporation rather than housed in a distinct entity (per company website, 2026).